Edgewise Therapeutics Inc. Common Stock vs General Mills, Inc. — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while General Mills, Inc. trades at $32.47 (market cap $17.02B). The key difference: General Mills, Inc. is far larger — about 4.3× Edgewise Therapeutics Inc. Common Stock's market cap, and General Mills, Inc. pays a 7.67% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and General Mills, Inc. for 107 Days on average.
| EWTX | GIS | |
|---|---|---|
Market Cap | $3.94B | $17.02B |
Volume | 810,104 | 7,979,067 |
Sector | Health | Consumer Staples |
52-Week High | $48.35 | $49.18 |
52-Week Low | $14.89 | $31.67 |
Typical Hold Time | 0 Days | 107 Days |
Enterprise Value | $3.48B | $30.20B |
Dividend Yield | — | 7.67% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
General Mills (GIS) trades at $32.11, down 1.8% on the day, reflecting recent pressure from a Q4 2025 earnings miss and a projected net loss for 2026. The stock shows a bearish technical trend, with key support at $32. Despite a low P/E of 9.23, profitability metrics like a negative ROE of -10.55% and a forecasted negative net income margin for 2026 highlight significant challenges. Recent news includes a CEO transition and a reaffirmed $0.61 quarterly dividend, but investor sentiment remains cautious amid declining revenues and margin pressures.
The outlook for GIS is clouded by execution risks in its turnaround strategy and macroeconomic headwinds. The high dividend yield offers income appeal, but the potential for a dividend cut and sustained earnings weakness presents substantial risk. Analyst consensus is predominantly Hold, with a $36 price target suggesting limited near-term upside, making the stock a speculative hold for income-focused investors tolerant of high risk.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →